China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a clinical study for its B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. The study was approved in China in September last year. This marks a significant milestone in the development of the drug, which is designed to treat non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia (ALL), and other malignant hematological tumors.
Drug Profile and Mechanism
ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor. It is being developed to treat various hematological malignancies, either as a monotherapy or in combination with BTK inhibitors and other drugs. BCL2 is a crucial regulatory protein in the apoptosis pathway, and its abnormal expression is linked to the development of several hematologic malignancies. ICP-248 works by selectively inhibiting BCL2, thereby restoring the mechanism of programmed cell death and exerting an anti-tumor effect.
Significance of the Clinical Trial
The initiation of the clinical study for ICP-248 highlights InnoCare Pharma’s commitment to advancing innovative therapies for hematological cancers. This development is expected to provide new treatment options for patients suffering from non-Hodgkin’s lymphoma, acute lymphoblastic leukemia, and other related conditions, potentially improving their quality of life and outcomes.-Fineline Info & Tech
